First-in-hu­man stud­ies in sight, SQZ's cell ther­a­py tech wins over a di­verse group of in­vestors in $72M round

7 years ago
R&D
Discovery

Third Rock­'s Am­bys hauls $140M for liv­er dis­ease, ink­ing Take­da deal ahead of launch

7 years ago
Financing
Startups

Sam­sung out­lines block­buster in­vest­ment plan for bio­phar­ma­ceu­ti­cals, part of a $22B play on next-gen tech

7 years ago
Financing
AI

Trump ad­min­is­tra­tion opens the door to low­er drug prices as Medicare Ad­van­tage plans are pushed to step ther­a­py ...

7 years ago
Pharma

14-year-old par­tial hold comes back to haunt Gem­phire, bat­ter­ing shares and wreck­ing time­lines

7 years ago
R&D
Pharma

Min­ing re­al world da­ta for drug de­vel­op­ment in­sights, Wood­ford-backed AI firm seeks $77M Lon­don IPO

7 years ago
Financing

Al­ler­gan picks up op­tion for Ed­i­tas' rare eye dis­ease drug; Cure­Ge­net­ics bags $17M

7 years ago
News Briefing

PAH ther­a­py tanks in Phase III, oblit­er­at­ing Bellerophon's stock

7 years ago
R&D

New re­port sin­gles out Big Phar­ma play­ers for ring­ing their block­busters with patents while hik­ing prices for years

7 years ago
Pharma

GSK chief Em­ma Walm­s­ley rounds out her top team with CFO pick — but per­for­mance lags

7 years ago
People
Bioregnum

Spark takes a beat­ing as he­mo­phil­ia safe­ty set­backs tor­pe­do stock, bur­nish ri­val Bio­Marin

7 years ago
R&D

NEA, 5AM back a $50M play to steer gene ther­a­pies to the clin­ic at Ak­ou­os — the lat­est start­up in hear­ing

7 years ago
Financing
Startups

Boehringer or­ga­nizes a coali­tion in search of first CF gene ther­a­py, work­ing with re­search, man­u­fac­tur­ing part­ners

7 years ago
R&D
Pharma

Pro­tag­o­nist rais­es $22M to re­vive PTG-100; Paratek's an­tibi­ot­ic shows non-in­fe­ri­or­i­ty

7 years ago
News Briefing

What's big­ger than a uni­corn? Sa­mumed stuns yet again as an­ti-ag­ing pipeline draws $438M at $12B val­u­a­tion

7 years ago
Financing

Block­buster dreams quashed, Iron­wood drops As­traZeneca's $1.3B gout drug dis­as­ter

7 years ago
Pharma

Who are the most pro­duc­tive drug de­vel­op­ers in bio­phar­ma? Our top-20 list has lots of sur­pris­es

7 years ago
R&D
Special

No sur­prise: FDA hands Pain Ther­a­peu­tics an­oth­er slap­down on Re­moxy, forc­ing a quick re­struc­tur­ing

7 years ago
R&D

Ovid's snap­shot of broad ef­fi­ca­cy da­ta for their PhII An­gel­man syn­drome tri­al can't stop a rout -- shares crushed

7 years ago
R&D

With PD-1 OK loom­ing, Re­gen­eron antes $100M on blue­bird al­liance for next-gen TCR cell ther­a­py pact

7 years ago
Pharma

That big HKEX biotech boom is start­ing to look shaky; Al­ny­lam gets a green light in the UK for patisir­an

7 years ago
News Briefing

Cell Med­ica scoops Kite Phar­ma's Chris Now­ers as CEO; Shire vet jumps to Edi­Gene as CEO

7 years ago
Peer Review

Lil­ly Asian Ven­tures backs Im­pact's PARP re­search again, chip­ping in for $30M Se­ries C led by Decheng Cap­i­tal

7 years ago
Financing
China

Roche gets some reg­u­la­to­ry love for its break­through quest on a PhI­II Hunt­ing­ton's drug

7 years ago
Pharma
First page Previous page 1020102110221023102410251026 Next page Last page
A service from the Financial Times